TY - JOUR
T1 - Seminal plasma proteins in prostatic carcinoma
T2 - Increased nuclear semenogelin i expression is a predictor of biochemical recurrence after radical prostatectomy
AU - Izumi, Koji
AU - Li, Yi
AU - Zheng, Yichun
AU - Gordetsky, Jennifer
AU - Yao, Jorge L.
AU - Miyamoto, Hiroshi
N1 - Funding Information:
Grant support: H. M. is supported by the Department of Defense Prostate Cancer Research Program (W81XWH-09-1-0305).
Copyright:
Copyright 2013 Elsevier B.V., All rights reserved.
PY - 2012/11
Y1 - 2012/11
N2 - Semenogelins and eppin are seminal plasma proteins that form a complex and inhibit sperm motility. However, the role of these proteins in prostate cancer is poorly understood. We immunohistochemically stained for semenogelins I and II and eppin in 291 radical prostatectomy specimens. We then evaluated the association between their expressions in nuclei, cytoplasms, or intraluminal secretions of benign/high-grade prostatic intraepithelial neoplasia/carcinoma cells and clinicopathologic profile available for our patient cohort. Stains were positive in 32%/77%/84% (nuclear semenogelin I), 87%/94%/84% (nuclear semenogelin II), 56%/64%/37% (nuclear eppin), 7%/15%/11% (cytoplasmic semenogelin I), 6%/11%/9% (cytoplasmic semenogelin II), 68%/74%/95% (cytoplasmic eppin), 97%/98%/13% (secreted semenogelin I), 98%/97%/11% (secreted semenogelin II), and 97%/98%/48% (secreted eppin) of benign/prostatic intraepithelial neoplasia/carcinoma, respectively. The levels of nuclear semenogelin I/cytoplasmic eppin were significantly higher in carcinoma than in benign (P <.001/P <.001) or prostatic intraepithelial neoplasia (P <.001/P <.001) and in prostatic intraepithelial neoplasia than in benign (P <.001/P =.006). Significantly higher nuclear semenogelin II expression was found in prostatic intraepithelial neoplasia than in benign (P <.001) or carcinoma (P <.001). Significantly lower nuclear eppin expression was seen in carcinoma than in benign (P <.001) or prostatic intraepithelial neoplasia (P <.001). Secreted semenogelin I, secreted semenogelin II, and secreted eppin were all significantly lower in carcinoma than in benign (P <.001) or prostatic intraepithelial neoplasia (P <.001). There were no statistically significant correlations between each stain and clinicopathologic features except significantly lower nuclear eppin expression in Gleason score 8 or higher tumors. Kaplan-Meier and log-rank tests further revealed that patients with nuclear semenogelin I-positive tumor had a significantly higher risk for biochemical recurrence (P =.046). Multivariate Cox model showed a trend toward significance (P =.093) in nuclear semenogelin I positivity as an independent predictor for recurrence. These results suggest that nuclear semenogelin I expression could be a reliable prognosticator in men who undergo radical prostatectomy.
AB - Semenogelins and eppin are seminal plasma proteins that form a complex and inhibit sperm motility. However, the role of these proteins in prostate cancer is poorly understood. We immunohistochemically stained for semenogelins I and II and eppin in 291 radical prostatectomy specimens. We then evaluated the association between their expressions in nuclei, cytoplasms, or intraluminal secretions of benign/high-grade prostatic intraepithelial neoplasia/carcinoma cells and clinicopathologic profile available for our patient cohort. Stains were positive in 32%/77%/84% (nuclear semenogelin I), 87%/94%/84% (nuclear semenogelin II), 56%/64%/37% (nuclear eppin), 7%/15%/11% (cytoplasmic semenogelin I), 6%/11%/9% (cytoplasmic semenogelin II), 68%/74%/95% (cytoplasmic eppin), 97%/98%/13% (secreted semenogelin I), 98%/97%/11% (secreted semenogelin II), and 97%/98%/48% (secreted eppin) of benign/prostatic intraepithelial neoplasia/carcinoma, respectively. The levels of nuclear semenogelin I/cytoplasmic eppin were significantly higher in carcinoma than in benign (P <.001/P <.001) or prostatic intraepithelial neoplasia (P <.001/P <.001) and in prostatic intraepithelial neoplasia than in benign (P <.001/P =.006). Significantly higher nuclear semenogelin II expression was found in prostatic intraepithelial neoplasia than in benign (P <.001) or carcinoma (P <.001). Significantly lower nuclear eppin expression was seen in carcinoma than in benign (P <.001) or prostatic intraepithelial neoplasia (P <.001). Secreted semenogelin I, secreted semenogelin II, and secreted eppin were all significantly lower in carcinoma than in benign (P <.001) or prostatic intraepithelial neoplasia (P <.001). There were no statistically significant correlations between each stain and clinicopathologic features except significantly lower nuclear eppin expression in Gleason score 8 or higher tumors. Kaplan-Meier and log-rank tests further revealed that patients with nuclear semenogelin I-positive tumor had a significantly higher risk for biochemical recurrence (P =.046). Multivariate Cox model showed a trend toward significance (P =.093) in nuclear semenogelin I positivity as an independent predictor for recurrence. These results suggest that nuclear semenogelin I expression could be a reliable prognosticator in men who undergo radical prostatectomy.
KW - Biochemical recurrence
KW - Eppin
KW - Prostate cancer
KW - Prostatectomy
KW - Semenogelin
UR - http://www.scopus.com/inward/record.url?scp=84867881583&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84867881583&partnerID=8YFLogxK
U2 - 10.1016/j.humpath.2012.02.008
DO - 10.1016/j.humpath.2012.02.008
M3 - Article
C2 - 22617231
AN - SCOPUS:84867881583
SN - 0046-8177
VL - 43
SP - 1991
EP - 2000
JO - Human Pathology
JF - Human Pathology
IS - 11
ER -